Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Ascentage Pharma Group Inc.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05415098CT.gov Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epithelioid Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Apg-5918 (this asset) | Ascentage Pharma Group Inc. | P1 | CC · 43 |
| Tazemetostat | Epizyme, Inc. | P2 | BB |
| Nab-Rapamycin | Sarcoma Oncology Research Center, LLC | P1/2 | CCC |
| Nivolumab | Sarcoma Oncology Research Center, LLC | P1/2 | CCC |
| Tiragolumab | National Cancer Institute (NCI) | P1/2 | CCC |
| Zoledronate | University of Florida | P1/2 | CCC |
| Atezolizumab | National Cancer Institute (NCI) | P1/2 | CCC |
| Epsametostat | Haihe Biopharma Co., Ltd. | P1/2 | CCC |
| Fludeoxyglucose | National Cancer Institute (NCI) | P1/2 | CCC |
+2 more in the Epithelioid Sarcoma cohort
Other indications for Apg-5918
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Castration-Resistant Prostate Carcinoma | — | P1 | CC · 43 |
| Nasopharyngeal Carcinoma | — | P1 | CC · 41 |
| B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Apg-5918 in Epithelioid Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/apg-5918-epithelioid-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →